Process intensification (PI) is no longer just a concept—it is a defining strategy shaping the future of upstream bioprocessing. Designed to increase productivity, throughput and streamline resource use, PI brings real-world benefits to biopharmaceutical manufacturing.
However, while PI holds great promise, its implementation can present significant complexity. Higher cell densities, tighter timelines and more sophisticated process control demand expertise, robust technology and tailored development approaches.
In this webinar, the expert speakers will explore the strategic application of PI across upstream workflows, including Intensified Fed-Batch (iFB), N-1 and N-stage perfusion, Hybrid Fed-Batch (hFB) and High-Density Cryo Seed Intermediates (HDCSI). Attendees will get to learn how these methods can elevate titer and volumetric productivities, simplify seed trains and reduce “unproductive” early-phase steps.
Beyond benefits, the expert speakers will address the challenges: increased process complexity, cell separation at high densities and the balance between speed and robustness. They will gain practical insights on how to mitigate these risks and apply PI in a manner that is fit-for-purpose for your molecule, timeline and scale.
Drawing from real project experience, the experts will share how PI can be integrated into bioproduction workflows to unlock performance while ensuring process safety, compliance and scalability.
Register now to gain actionable guidance on leveraging process intensification to future-proof upstream strategies—and see how the right CDMO partnership can make all the difference.
Speakers
Dr. Nathalie Rigal, Head of Upstream Process Development, ProBioGen
Dr. Nathalie Rigal is the Head of Upstream Process Development at ProBioGen, with over 15 years of experience in biopharmaceutical development. She joined the company in 2018 as a Research Scientist and was appointed Head of USP Development in 2021.
Previously, Nathalie worked at Glycotope GmbH (now FyoniBio), where she completed an industry PhD and later led the cell line and bioprocess development team. Earlier in her career, she held roles at Evotec SE in protein production for high throughput screening and at Lonza Biologics (UK), specializing on upstream process development and validation.
Message Presenter
Lukas Rositzka, Head of Upstream Processing Production, ProBioGen
Lukas Rositzka is Head of Upstream Processing Production at ProBioGen. He has over 10 years of experience in industrial biotechnology, particularly in the CDMO sector. His work has focused on upstream process development, scale-up and GMP manufacturing of therapeutic proteins.
Lukas played a key role in the start-up of two GMP facilities and has been involved in implementing new technologies and process optimization strategies. He holds a Master of Science degree in Molecular Biotechnology from the University of Bielefeld.
Message PresenterWho Should Attend?
This webinar is ideal for professionals in biopharmaceutical development and manufacturing who are seeking to improve upstream process performance through advanced strategies like PI. Relevant roles include:
- Upstream Process Development Scientists and Engineers
- Bioprocessing and Manufacturing Leads
- Cell Line Development and Tech Transfer Specialists
- CMC and Program Managers
- Biotech Executives and Decision-Makers evaluating CDMO partnerships
What You Will Learn
Attendees will learn about:
- What PI means for improving workflow speed and process yield
- When and how to apply iFB, perfusion and HDCSI to streamline bioproduction
- Why PI can be complex to implement—and how to mitigate associated risks
- How partnering with an expert CDMO ensures a smooth transition to intensified manufacturing, relying on advanced technologies, risk mitigation and key expertise
Xtalks Partner
ProBioGen
As a fully integrated contract development and manufacturing organization (CDMO), ProBioGen specializes in developing and manufacturing biopharmaceutical active ingredients, such as monoclonal antibodies, cytokines, clotting factors, as well as viral vectors, and vaccines. We optimize molecules, develop high-performance cell lines and robust processes to ensure efficient and reliable production of biopharmaceutical candidates. Leveraging our proprietary technologies, we deliver outstanding process yields and ensure superior product potency and quality.
In the protein business, we offer enhanced protein production services, including cell line development and comprehensive process development with scale-down models, integrated upstream and downstream process (USP/DSP) optimization, and early risk detection, designed to ensure scalability to our in-house GMP manufacturing. Our platform processes are streamlined for accelerated timelines, and our in-depth knowledge on cell line and process development, including process intensification enable us to address even the most complex challenges with tailored solutions that ensure high quality and yield.
For more information about ProBioGen visit our website or follow us on LinkedIn.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account